Alumis Inc.

Alumis is a biotechnology company developing medicines to treat autoimmune diseases, where the body's immune system attacks itself. The company's main drug candidate is envudeucitinib, designed to treat plaque psoriasis and lupus by blocking a protein called TYK2. Alumis is also working on several other experimental drugs targeting different parts of the immune system to treat conditions like thyroid eye disease and neuroinflammatory diseases. The company is still in the clinical testing phase, meaning its drugs have not yet been approved by regulators for patients to use.